Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients

in Endocrine-Related Cancer
(Correspondence should be addressed to B Győrffy who is now at First Department of Pediatrics, Semmelweis University, Bókay János u. 53-54, H-1083 Budapest, Hungary; Email: gyorffy@kmplot.com)

The validation of prognostic biomarkers in large independent patient cohorts is a major bottleneck in ovarian cancer research. We implemented an online tool to assess the prognostic value of the expression levels of all microarray-quantified genes in ovarian cancer patients. First, a database was set up using gene expression data and survival information of 1287 ovarian cancer patients downloaded from Gene Expression Omnibus and The Cancer Genome Atlas (Affymetrix HG-U133A, HG-U133A 2.0, and HG-U133 Plus 2.0 microarrays). After quality control and normalization, only probes present on all three Affymetrix platforms were retained (n=22 277). To analyze the prognostic value of the selected gene, we divided the patients into two groups according to various quantile expressions of the gene. These groups were then compared using progression-free survival (n=1090) or overall survival (n=1287). A Kaplan–Meier survival plot was generated and significance was computed. The tool can be accessed online at www.kmplot.com/ovar. We used this integrative data analysis tool to validate the prognostic power of 37 biomarkers identified in the literature. Of these, CA125 (MUC16; P=3.7×10−5, hazard ratio (HR)=1.4), CDKN1B (P=5.4×10−5, HR=1.4), KLK6 (P=0.002, HR=0.79), IFNG (P=0.004, HR=0.81), P16 (P=0.02, HR=0.66), and BIRC5 (P=0.00017, HR=0.75) were associated with survival. The combination of several probe sets can further increase prediction efficiency. In summary, we developed a global online biomarker validation platform that mines all available microarray data to assess the prognostic power of 22 277 genes in 1287 ovarian cancer patients. We specifically used this tool to evaluate the effect of 37 previously published biomarkers on ovarian cancer prognosis.

Abstract

The validation of prognostic biomarkers in large independent patient cohorts is a major bottleneck in ovarian cancer research. We implemented an online tool to assess the prognostic value of the expression levels of all microarray-quantified genes in ovarian cancer patients. First, a database was set up using gene expression data and survival information of 1287 ovarian cancer patients downloaded from Gene Expression Omnibus and The Cancer Genome Atlas (Affymetrix HG-U133A, HG-U133A 2.0, and HG-U133 Plus 2.0 microarrays). After quality control and normalization, only probes present on all three Affymetrix platforms were retained (n=22 277). To analyze the prognostic value of the selected gene, we divided the patients into two groups according to various quantile expressions of the gene. These groups were then compared using progression-free survival (n=1090) or overall survival (n=1287). A Kaplan–Meier survival plot was generated and significance was computed. The tool can be accessed online at www.kmplot.com/ovar. We used this integrative data analysis tool to validate the prognostic power of 37 biomarkers identified in the literature. Of these, CA125 (MUC16; P=3.7×10−5, hazard ratio (HR)=1.4), CDKN1B (P=5.4×10−5, HR=1.4), KLK6 (P=0.002, HR=0.79), IFNG (P=0.004, HR=0.81), P16 (P=0.02, HR=0.66), and BIRC5 (P=0.00017, HR=0.75) were associated with survival. The combination of several probe sets can further increase prediction efficiency. In summary, we developed a global online biomarker validation platform that mines all available microarray data to assess the prognostic power of 22 277 genes in 1287 ovarian cancer patients. We specifically used this tool to evaluate the effect of 37 previously published biomarkers on ovarian cancer prognosis.

Introduction

With a mortality of 8.4 per 100 000 women, ovarian cancer is the most common cause of death among gynecological malignancies (http://seer.cancer.gov) with a 5-year survival rate of 10–30%. Relative to breast cancer, the molecular characteristics of epithelial ovarian cancer (EOC) are more heterogeneous. Despite extensive research, clinical–pathological factors including tumor stage, residual disease after surgery, histological type, and tumor grade are still the most important features related to patient outcome. To date, only two biomarkers have been approved by the Food and Drug Administration (FDA) for monitoring patients with EOC: CA125 (MUC16; Gadducci et al. 1995, 2004, Cooper et al. 2002, Riedinger et al. 2006) and HE4 (WFDC2; Huhtinen et al. 2009, Moore et al. 2009, 2010).

Several additional genes have been suggested as potential biomarkers for the progression of EOC. Low expression of p21 (Ferrandina et al. 2000, Plisiecka-Halasa et al. 2003, Bali et al. 2004), bax (Tai et al. 1998, Skirnisdottir et al. 2001), and hTERT (Brustmann 2005) and high expression of survivin (Sui et al. 2002), VEGFR (Hefler et al. 2006), p53 (Buttitta et al. 1997, Reles et al. 2001), human kallikrein 6 (Diamandis et al. 2003), human kallikrein 10 (Luo et al. 2001), Interleukin 6 (Scambia et al. 1995), p27 (Newcomb et al. 1999, Masciullo et al. 2000, Korkolopoulou et al. 2002, Schmider-Ross et al. 2006), cyclin D1 (Bali et al. 2004, Barbieri et al. 2004), cyclin D3 (Levidou et al. 2007), cyclin E (Sui et al. 2001, Farley et al. 2003, Rosen et al. 2006, Bedrosian et al. 2007), Bcl-xL (Materna et al. 2007), cIAP (Psyrri et al. 2006), and ERBB1 (Skirnisdottir et al. 2004, Psyrri et al. 2005) could represent prognostic variables for poor clinical outcome. In addition, the genome-wide investigation of adequate clinical cohorts delivers unprecedented amount of potential new biomarkers (Denkert et al. 2009).

However, most of these potential biomarkers have neither been validated in multivariate analyses nor was their discriminative power validated in large clinical cohorts. Even more alarmingly, many reports have questioned or rejected a correlation between a proposed biomarker and clinical outcome. Doubts were raised regarding the markers CA125 (Cruickshank et al. 1987, van der Burg et al. 1988, Rustin et al. 1989, Sevelda et al. 1989), cyclin D1 (Masciullo et al. 1997, Dhar et al. 1999), p16 (Milde-Langosch et al. 2003, Khouja et al. 2007), p21 (Baekelandt et al. 1999, Levesque et al. 2000, Schuyer et al. 2001), p27 (Schmider et al. 2000), p53 (Smith-Sorensen et al. 1998, Wang et al. 2004, Green et al. 2006), Bcl-xl (Baekelandt et al. 2000), cIAP (Kleinberg et al. 2007), survivin (Cohen et al. 2003, Ferrandina et al. 2005), hTERT (Wisman et al. 2003, Widschwendter et al. 2004), ERBB1 (Berchuck et al. 1991, Meden et al. 1995, Nielsen et al. 2004), and ERBB2 (Rubin et al. 1993, Meden et al. 1995, Ross et al. 1999, Nielsen et al. 2004, Riener et al. 2004).

Given the large number of potential biomarkers for EOC, the immediate challenge is to validate the most robust candidates eligible for further investigation. Recent advances in genomic technologies together with powerful bioinformatic tools can enable us to deliver this prerequisite. We recently developed an online biomarker validation tool using microarray data of 2000 breast cancer patients (Gyorffy et al. 2010). In this, the expression of a selected gene can be used to split patients into groups, and the proportional survival of these groups is compared to each other.

In this study, our aim was to implement an online survival analysis tool for the rapid assessment of prognosis-related genes in ovarian cancer and to test the validity of previously proposed biomarkers. Furthermore, we also developed additional analysis options including the computation of multigenic prognosis predictors and the option of grouping patients based on applied treatment protocols.

Materials and methods

Collection of ovarian cancer microarray data sets

We searched Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) and The Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov) to identify data sets suitable for the analysis. In this, the keywords ‘ovarian’, ‘cancer’, ‘survival’, ‘gpl96’, ‘gpl570’, and ‘gpl571’ were used. Only publications with available raw microarray gene expression data, clinical survival information, and at least 20 patients were included. Only three microarray platforms, GPL96 (Affymetrix HG-U133A), GPL570 (Affymetrix HG-U133 Plus 2.0), and GPL571/GPL3921 (Affymetrix HG-U133A 2.0), were considered because they are frequently used and because these particular arrays have 22 277 probe sets (representing 13 435 unique genes) in common. The use of almost identical platforms and identical probe sets is vital because different platforms for gene expression profiling measure expression of the same gene with varying accuracy, on different relative scales, and with diverse dynamic ranges (Tan et al. 2003). Finally, we controlled all samples using the ranked expression of all genes to identify repeatedly published microarrays.

Setup of server for online survival calculation

The raw.CEL files were MAS5 normalized in the R statistical environment (www.r-project.org) using the affy Bioconductor library (Gautier et al. 2004). MAS5 can be applied to individual chips, making future extensions of the database uncomplicated. Furthermore, MAS5 ranked among the best normalization methods when compared with the results of RT-PCR measurements in our recent study (Gyorffy et al. 2009). For the analysis, only probes measured on GPL96, GPL570, and GPL571/GPL3921 were retained (n=22 277). At this stage, we performed a second scaling normalization to set the average expression on each chip to 1000. Although this technique cannot remove all, but it can significantly reduce batch effects (Sims et al. 2008). We integrated the gene expression and clinical data using PostgreSQL, an open-source object-relational database system (www.postgresql.org). Data security is ensured through PostgreSQL permissions that are imposed on individual tables in the project databases.

The KMplot web application can be reached in a platform-independent user interface. The interactivity of the service is increased by the usage of JavaScript and Ajax technologies. The server is hosted on Debian Linux (www.debian.org) and is powered by Apache (www.apache.org). he server-side scripts were developed in hypertext preprocessor (PHP), which controls the analysis requests and delivers the results. Open Database Connectivity is used as a middleware layer between the R and the PostgreSQL database via the RODBC package (cran.r-project.org/package=RODBC). The package ‘survival’ is used to calculate and plot Kaplan–Meier survival curves, and the number-at-risk is indicated below the main plot. Hazard ratio (HR; and 95% confidence intervals) and logrank P are calculated and displayed. The central server for the Kaplan–Meier plotter for ovarian cancer can be reached at www.kmplot.com/ovar.

Probe set options

We also implemented a set of probe-set-related options, including the option to use all probe sets available for a given gene on the microarray simultaneously and to use a combined expression of several probe sets. Using this option, it is possible to assess the effect of the mean expression of gene combinations on survival.

In addition, bee swarm plot can be drawn using the beeswarm package (www.cbs.dtu.dk/∼eklund/beeswarm/). The bee swarm plot is capable of visualizing gene expression as nonoverlapping points in a one-dimensional scatter plot. A bee swarm plot can be used to quickly identify outlier samples and genes with bimodal distribution.

Validation of previously published EOC biomarkers

A PubMed search was performed using the keywords ‘ovarian cancer’, ‘survival’, ‘biomarker’, and ‘gene expression’ to identify genes described in the literature as potential EOC biomarkers. Then, using PubMed gene, we added a unique gene symbol for each of the genes and identified the corresponding Affymetrix probe set IDs. The capability of these genes to predict survival was measured by using the probe set IDs in the online analysis tool.

In the combination of several markers, their mean expression is first computed for each sample. Then, the median of these is used for splitting the patients into cohorts during the analysis.

Results

Construction of combined ovarian cancer microarray database

We identified 1287 unique patients in eight data sets meeting our criteria in GEO and TCGA. In the GSE3149 data set, we found two samples repeatedly published (GSM70546=GSM70547 and GSM70511=GSM70512). As for these samples the unique recognition of the appropriate clinical information was not possible, we removed them from the final database. Of the above, 72% have serous and 2% have endometrioid tumors. Patients are distributed across stage 1 (n=34, 3.6%), stage 2 (n=122, 13%), stage 3 (n=672, 71.7%), and stage 4 (n=109, 11.6%). Debulking was optimal (residual tumor <1 cm) in 674 out of 1119 patients. The median overall survival is 31.0 months, 1090 patients have progression-free survival data, and 1287 have overall survival data. (note: some publications report ‘disease-free survival’ (Konstantinopoulos et al. 2010) or ‘relapse-free survival’ (Tothill et al. 2008) instead of ‘progression-free survival’. These were merged as ‘progression-free survival’ to enable a meta-analysis of the complete database.). A summary of the clinical characteristics of the patients in each data set used in the analysis is shown in Table 1.

Table 1

Clinical properties of the ovarian cancer patients used in the analysis

GEO IDReferenceGEO platformNo. of samples in data setDeath eventMedian overall survivalSerous/endometrioidGrade (1/2/3)Stage (1/2/3/4)Debulk optimal (/out of)Treatment contains platin (/out of)Treatment contains Taxol (/out of)
GSE14764Denkert et al. 2009GPL96802135.268/7NANA27/2978/7979/79
GSE15622Ahmed et al. 2007GPL571352827.031/00/7/280/0/26/9NA20/3515/35
GSE19829Konstantinopoulos et al. 2010GPL570281735.0NANANANANANA
GSE3149Bild et al. 2006GPL961166934.0NA4/55/540/1/96/1464/117115/11594/115
GSE9891Tothill et al. 2008GPL57028511028.0264/2024/18/21719/97/164/0160/229242/282195/282
GSE18520Mok et al. 2009GPL570534122.053/00/0/53NANANANA
GSE26712NAGPL9618512938.7NANANA90/185NANA
TCGATCGA 2011GPL392150527730.6505/05/62/42715/24/386/81333/452458/473233/468
Total128769231.0925/2733/142/77934/122/672/109674/1121914/985616/980

NA, data not available; /out of, total number of patients with available clinical data.

Setup of online survival analysis platform

The Kaplan–Meier plot shows the association between the investigated marker and survival in which the samples are grouped according to the median (or upper or lower quartile) expression of the selected gene. Before running the analysis, the patients can be filtered using stage, histology, grade, and treatment parameters including debulking status and applied chemotherapy. In addition, as an alternative to progression-free survival, overall survival can also be investigated.

Since there is an already established biomarker (CA125), a clinician might be interested in a specific clinical cohort of patients having low CA125 levels. Therefore, we added an additional filtering option in which only patients having an average CA125 expression (average of the two reliable probe sets) below the lower quartile of all patients are included. We must note that while this study measured tissue levels of CA125, the FDA-approved test for ovarian cancer is serum based.

Validation of previously published EOC biomarkers

Markers of ovarian cancer prognosis have been identified using literature search. We computed Kaplan–Meier plots for 37 proposed biomarkers to assess their effect on prognosis (for the complete results see Table 2 and Fig. 1). All biomarkers were investigated in the same cohort in which they were discovered. High significance was achieved for CA125, KLK6, IFNG, P15, P16, CDKN1B, and BIRC5. In addition, we have also run the analysis for predicting progression-free survival in all patients.

Table 2

The association between prognostic markers and progression-free survival. The patients were divided into two groups as having higher or lower expression as compared to the median. The markers were analyzed in subsets of patients with equivalent clinical characteristics to the cohorts in which the association has previously been described

SymbolGeneReferenceSurvivalAnalyzed in the cohort ofAffymetrix IDQHRP
CA(MUC 16)125CA 125Gadducci et al. 1995, Cooper et al. 2002, Gadducci et al. 2004, Riedinger et al. 2006PFSAll patients220196_at2NSNS
201384_s_at11.30.0003*
201383_s_at11.43.7×10−5*,a
KRT19Cytokeratin 19Tempfer et al. 1998, Gadducci et al. 2001PFSDebulk=subopt.201650_at1NSNS
KLK6Kallikrein 6Diamandis et al. 2003PFSAll patients216699_s_at20.790.002*
204733_at1NSNS
KLK10Kallikrein 10Luo et al. 2001PFSStage=3+4209792_s_at1NSNS
215808_at3NSNS
IL6Interleukin 6Scambia et al. 1995OSAll patients205207_at2NSNS
IL7Interleukin 7Lambeck et al. 2007OSAll patients206693_at3NSNS
IFNGγ-InterferonMarth et al. 2004PFSAll patients210354_at30.810.004*
FASsFasHefler et al. 2000, Konno et al. 2000PFSAll patients204780_s_at11.20.017
204781_s_at1NSNS
212218_s_at10.840.024
215719_x_at2NSNS
216252_x_at2NSNS
217006_x_at3NSNS
VEGFRVEGFRHefler et al. 2006OSAll patients203934_at21.20.064
CCND1Cyclin D1Bali et al. 2004, Barbieri et al. 2004OSStage=3+4208711_s_at1NSNS
208712_at1NSNS
CCND3Cyclin D3Levidou et al. 2007OSAll patients201700_at1NSNS
CCNECyclin ESui et al. 2001, Farley et al. 2003, Rosen et al. 2006, Bedrosian et al. 2007OSDebulk=subopt.213523_at2NSNS
205034_at2NSNS
211814_s_at3NSNS
P(CDK N2B)15p15Kudoh et al. 2002PFSAll patients204599_s_at1NSNS
212857_x_at11.30.0005*
214512_s_at11.20.01
221727_at3NSNS
218708_at1NSNS
P(CDK N2A)16p16Katsaros et al. 2004, Kommoss et al. 2007PFSDebulk=subopt.207039_at20.660.002*
209644_x_at1NSNS
211156_at30.690.009
CDKN1Ap21Ferrandina et al. 2000, Plisiecka-Halasa et al. 2003, Bali et al. 2004PFSHistology=serous202284_s_at1NSNS
CDKN1Bp27Newcomb et al. 1999, Masciullo et al. 2000, Korkolopoulou et al. 2002, Schmider-Ross et al. 2006PFSAll patients209112_at11.45.4×10−5*,a
RB1pRBDong et al. 1997, Konstantinidou et al. 2003OSStage=1203132_at1NSNS
211540_s_at3NSNS
E2F1E2F1Suh et al. 2008PFSAll patients2028_s_at10.830.017
3NSNS
E2F2E2F2Reimer et al. 2007PFSAll patients207042_at30.860.037
E2F4E2F4Reimer et al. 2007PFSAll patients202248_at30.850.034
38707_r_at1NSNS
TP53p53Buttitta et al. 1997, Reles et al. 2001PFSStage=3+4211300_s_at2NSNS
201746_at10.840.075
TP73p73Becker et al. 2006OSAll patients220804_s_at3NSNS
BAXbaxTai et al. 1998, Skirnisdottir et al. 2001PFSTherapy=contains Taxol208478_s_at2NSNS
211833_s_at2NSNS
BCL2L1Bcl-xlMaterna et al. 2007PFSAll patients212312_at10.860.04
215037_s_at2NSNS
206665_s_at3NSNS
BIRC2cIAPPsyrri et al. 2006OSStage=3+4202076_at1NSNS
BIRC5SurvivinSui et al. 2002PFSAll patients210334_x_at20.750.00017*
202094_at20.840.018
202095_s_at10.840.018
TERThTERTBrustmann 2005OSHistology=serous207199_at3NSNS
EGFRERBB1Skirnisdottir et al. 2004, Psyrri et al. 2005PFSStage=1+2201983_s_at1NSNS
201984_s_at1NSNS
211551_at2NSNS
210984_x_at3NSNS
211550_at3NSNS
211607_x_at3NSNS
ERBB2ERBB2Lassus et al. 2004PFSHistology=serous210930_s_at3NSNS
216836_s_at1NSNS
METc-MetSawada et al. 2007OSStage=3+4217828_at1NSNS
203510_at1NSNS
211599_x_at1NSNS
213807_x_at2NSNS
213816_s_at3NSNS
MMP2MMP-2Torng et al. 2004PFSHistology=endom.201069_at10.330.05
MMP9MMP-9Sillanpaa et al. 2007OSStage=1203936_s_at1NSNS
MMP14MT1-MMPKamat et al. 2006OSStage=2+3+4160020_at1NSNS
202828_s_at1NSNS
202827_s_at2NSNS
217279_x_at3NSNS
WFDC2 (HE4)Epididymis protein 4Huhtinen et al. 2009, Moore et al. 2009, 2010PFSAll patients203892_at1NSNS
SERPINB5MaspinSecord et al. 2006PFSDebulk=subopt.204855_at1NSNS
BRCA1BRCA1Thrall et al. 2006OSAll patients211851_x_at30.820.01
204531_s_at2NSNS
ERCC1ERCC1Darcy & Tian 2007PFSStage=3203719_at1NSNS
Therapy=Tax+Plat203720_s_at1NSNS

PFS, progression-free survival; OS, overall survival, HR, hazard ratio; Q, quality score for the probe set as measured after normalization across the entire data set (1, average expression over 500 or maximal expression over 1000; 2, intermediate probes; 3, average expression below 100); NS, not significant (significance over 0.05). *bold indicates P<0.005.

Figure 1
Figure 1

Survival plots depicting the good prognostic effect on progression-free survival of the lower expression of CA125 (A, 201383_s_at), CDKN1B (B, 209112_at), and P15 (C, 212857_x_at). Classification using the mean expression of two genes (CA125+CDKN1B) with a cutoff at the lower quartile results in increased discriminative power (D).

Citation: Endocrine-Related Cancer 19, 2; 10.1530/ERC-11-0329

Download Figure

In an effort to improve accuracy, a pair-wise combination of the three best performing probe sets was assessed independently. The combination of CA125 and CDKN1B with a cutoff at the lower quartile resulted in classification significance superior to the power of the markers independently (HR=1.5 and P=5.4×10−6 vs HR=1.4, P=3.7×10−5 and HR=1.4, P=5.4×10−5 for CA125 and CDKN1B, respectively, see Table 2 and Fig. 1).

Discussion

The validation of prognostic biomarkers is a major bottleneck in ovarian cancer research. Here, we combined multiple large microarray data sets to increase the statistical power for a meta-analysis of 22 277 genes. We developed a freely accessible online tool to estimate the prognostic value of any selected gene in a large cohort of clinical patients. After dividing the patients into two groups based on the expression of the selected gene, a Kaplan–Meier plot is generated. The implemented computations are performed in real time on our server. This enables seamless future extension using new data sets or new filtering options.

We have integrated data sets from GEO and TCGA – ∼40% of samples used by www.kmplot.com/ovar are from the TCGA repository. For the TCGA samples alone, there is an option to perform analyses in the caIntegrator website (https://caintegrator.nci.nih.gov). The samples in TCGA are open access or restricted (access is granted to NIH staff and to eRA Commons principal investigators) – however, the Affymetrix HG-U133 microarray profiles for the ovarian cancer patients are publicly available. We plan to continuously incorporate new GEO data sets as well as new TCGA samples in www.kmplot.com.

In contrast to breast cancer, where several already approved markers are in clinical use, in ovarian cancer only minimal progress has been made in recent years. When investigating the previously proposed biomarkers, we found that only few genes are actually capable of predicting outcome in our combined data set: CA125, P15, KLK6, IFNG, P16, CDKN1B, and BIRC5. Of these, CA125 and CDKN1B resulted in very robust significance. These results may reflect the high genetic heterogeneity of ovarian cancer (Gyorffy et al. 2008) and emphasize the importance of potential improvements in prognosis.

The most extensively studied marker for EOC is CA125 (Gadducci et al. 1995, 2004, Cooper et al. 2002, Riedinger et al. 2006), and determining its concentration in serum is essential for monitoring ovarian cancer progression. Fifty percent increase in serum CA125 level has been correlated to progression, and present progression definition of the Gynecological Cancer Intergroup defines progression based on two elevated serum CA125 levels. According to our results, tumor level of CA125 gene was able to predict later clinical outcome. Notably, we observed two different probe sets representing CA125 as significant. A third probe set did not show significant prognostic power, but it has also displayed low quality in terms of average expression as compared to the probe sets with significant prognostic power.

The role of the cell cycle control gene p27 (CDKN1B) as a prognostic marker in ovarian cancer was suggested in several studies (Newcomb et al. 1999, Masciullo et al. 2000, Korkolopoulou et al. 2002, Schmider-Ross et al. 2006). In addition, numerous recent analyses also confirmed its role in 205 (Lee et al. 2011), 131 (Skirnisdottir et al. 2011), and 339 (Duncan et al. 2010) patients. p27 is measured by only one probe set on the microarrays, and this probe set delivered high prognostic power in our analysis.

P15 is a tumor suppressor gene previously associated with ovarian cancer progression in 45 patients (Kudoh et al. 2002). The methylation status of P15 has also been investigated but was not an independent prognostic factor in 145 patients (Tam et al. 2007). One of the probe sets measuring P15 (212857_x_at) delivered a high prognostic potential.

To this point, we have investigated the prognostic power of individual probe sets. However, recent reports based on genomic technologies use not only single selected genes, but also a combination of these. In addition, some of the markers are not related to ovarian cancer prognosis in general, but have discriminative potential in one of the subgroups, or are related to different treatment regimens. While the evaluation of all potential markers and all eligible combinations is beyond the scope of this study, our online tool was set up exactly to enable researchers to perform these tests on our database.

In summary, we reviewed previously reported biomarkers of ovarian cancer prognosis and assessed their performance in a meta-analysis of 1297 ovarian cancer patients. We also developed an online biomarker validation platform to mine all available microarray data to assess the prognostic power of 22 277 genes.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

B Győrffy study was supported by the OTKA PD 83154, by the TAMOP-4.2.1.B-09/1/KMR-2010-0001, by the ETT 029/2009 grant and by the Alexander von Humboldt Stiftung. Z Szállási was supported by the Breast Cancer Research Foundation.

References

 

An official journal of

Society for Endocrinology

Sections

Figures

  • Survival plots depicting the good prognostic effect on progression-free survival of the lower expression of CA125 (A, 201383_s_at), CDKN1B (B, 209112_at), and P15 (C, 212857_x_at). Classification using the mean expression of two genes (CA125+CDKN1B) with a cutoff at the lower quartile results in increased discriminative power (D).

    View in gallery

References

AhmedAAMillsADIbrahimAETempleJBlenkironCViasMMassieCEIyerNGMcGeochACrawfordR2007The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell12514527. doi:10.1016/j.ccr.2007.11.014.

BaekelandtMHolmRTropeCGNeslandJMKristensenGB1999Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clinical Cancer Research528482853.

BaekelandtMHolmRNeslandJMTropeCGKristensenGB2000Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. Journal of Clinical Oncology1837753781.

BaliAO'BrienPMEdwardsLSSutherlandRLHackerNFHenshallSM2004Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clinical Cancer Research1051685177. doi:10.1158/1078-0432.CCR-03-0751.

BarbieriFLorenziPRagniNSchettiniGBruzzoCPedullaFAlamaA2004Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. Oncology66310315. doi:10.1159/000078332.

BeckerKPancoskaPConcinNVanden HeuvelKSladeNFischerMChalasEMollUM2006Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers. International Journal of Oncology29889902.

BedrosianILeeCTuckerSLPallaSLLuKKeyomarsiK2007Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy. Clinical Cancer Research1348004806. doi:10.1158/1078-0432.CCR-07-0142.

BerchuckARodriguezGCKamelADodgeRKSoperJTClarke-PearsonDLBastRCJr1991Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. American Journal of Obstetrics and Gynecology164669674.

BildAHYaoGChangJTWangQPottiAChasseDJoshiMBHarpoleDLancasterJMBerchuckA2006Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature439353357. doi:10.1038/nature04296.

BrustmannH2005Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Gynecological Oncology98396402. doi:10.1016/j.ygyno.2005.04.035.

van der BurgMELammesFBvan PuttenWLStoterG1988Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecological Oncology30307312. doi:10.1016/0090-8258(88)90244-2.

ButtittaFMarchettiAGadducciAPellegriniSMorgantiMCarnicelliVCosioSGagettiOGenazzaniARBevilacquaG1997p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. British Journal of Cancer75230235. doi:10.1038/bjc.1997.38.

CohenCLohmannCMCotsonisGLawsonDSantoianniR2003Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Modern Pathology16574583. doi:10.1097/01.MP.0000073868.31297.B0.

CooperBCSoodAKDavisCSRitchieJMSoroskyJIAndersonBBullerRE2002Preoperative CA125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstetrics and Gynecology1005964. doi:10.1016/S0029-7844(02)02057-4.

CruickshankDJFullertonWTKlopperA1987The clinical significance of pre-operative serum CA 125 in ovarian cancer. British Journal of Obstetrics and Gynaecology94692695. doi:10.1111/j.1471-0528.1987.tb03177.x.

DarcyKMTianCReedE2007A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum–taxane chemotherapy. Cancer Research6744744481. doi:10.1158/0008-5472.CAN-06-4076.

DenkertCBudcziesJDarb-EsfahaniSGyorffyBSehouliJKonsgenDZeillingerRWeichertWNoskeABuckendahlAC2009A prognostic gene expression index in ovarian cancer – validation across different independent data sets. Journal of Pathology218273280. doi:10.1002/path.2547.

DharKKBraniganKParkesJHowellsREHandPMusgroveCStrangeRCFryerAARedmanCWHobanPR1999Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells. British Journal of Cancer8111741181. doi:10.1038/sj.bjc.6690826.

DiamandisEPScorilasAFracchioliSVan GramberenMDe BruijnHHenrikASoosaipillaiAGrassLYousefGMStenmanUH2003Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. Journal of Clinical Oncology2110351043. doi:10.1200/JCO.2003.02.022.

DongYWalshMDMcGuckinMACummingsMCGabrielliBGWrightGRHurstTKhooSKParsonsPG1997Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. International Journal of Cancer74407415. doi:10.1002/(SICI)1097-0215(19970822)74:4<407::AID-IJC8>3.0.CO;2-Z.

DuncanTJAl-AttarARollandPHarperSSpendloveIDurrantLG2010Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer. International Journal of Gynecological Pathology29818. doi:10.1097/PGP.0b013e3181b64ec3.

FarleyJSmithLMDarcyKMSobelEO'ConnorDHendersonBMorrisonLEBirrerMJ2003Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Research6312351241.

FerrandinaGStolerAFagottiAFanfaniFSaccoRDe PasquaAMancusoSScambiaG2000p21WAF1/CIP1 protein expression in primary ovarian cancer. International Journal of Oncology1712311235.

FerrandinaGLeggeFMartinelliERanellettiFOZannoniGFLauriolaLGessiMGallottaVScambiaG2005Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. British Journal of Cancer92271277. doi:10.1038/sj.bjc.6602332.

GadducciAZolaPLandoniFMagginoTSartoriEBergaminoTCristofaniR1995Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecological Oncology584247. doi:10.1006/gyno.1995.1181.

GadducciAFerdeghiniMCosioSFanucchiACristofaniRGenazzaniAR2001The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. International Journal of Gynecological Cancer11277282. doi:10.1046/j.1525-1438.2001.011004277.x.

GadducciACosioSFanucchiANegriSCristofaniRGenazzaniAR2004The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecological Oncology93131136. doi:10.1016/j.ygyno.2003.12.043.

GautierLCopeLBolstadBMIrizarryRA2004Affy – analysis of Affymetrix GeneChip data at the probe level. Bioinformatics20307315. doi:10.1093/bioinformatics/btg405.

GreenJABernsEMCoensCvan LuijkIThompson-HehirJvan DiestPVerheijenRHvan de VijverMvan DamPKenterGG2006Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). European Journal of Cancer4225392548. doi:10.1016/j.ejca.2006.06.015.

GyorffyBDietelMFeketeTLageH2008A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma. International Journal of Gynecological Cancer1812151233. doi:10.1111/j.1525-1438.2007.01169.x.

GyorffyBLanczkyAEklundACDenkertCBudcziesJLiQSzallasiZ2010An online survival analysis tool to rapidly assess the effect of 22 277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Research and Treatment123725731.

GyorffyBMolnarBLageHSzallasiZEklundAC2009Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS ONE4e5645doi:10.1371/journal.pone.0005645.

HeflerLMayerhoferKNardiAReinthallerAKainzCTempferC2000Serum soluble Fas levels in ovarian cancer. Obstetrics and Gynecology966569. doi:10.1016/S0029-7844(00)00840-1.

HeflerLAZeillingerRGrimmCSoodAKChengWFGadducciATempferCBReinthallerA2006Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecological Oncology103512517. doi:10.1016/j.ygyno.2006.03.058.

HuhtinenKSuvitiePHiissaJJunnilaJHuvilaJKujariHSetalaMHarkkiPJalkanenJFraserJ2009Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. British Journal of Cancer10013151319. doi:10.1038/sj.bjc.6605011.

KamatAAFletcherMGrumanLMMuellerPLopezALandenCNJrHanLGershensonDMSoodAK2006The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clinical Cancer Research1217071714. doi:10.1158/1078-0432.CCR-05-2338.

KatsarosDChoWSingalRFracchioliSRigault De La LongraisIAArisioRMassobrioMSmithMZhengWGlassJ2004Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecological Oncology94685692. doi:10.1016/j.ygyno.2004.06.018.

KhoujaMHBaekelandtMNeslandJMHolmR2007The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. International Journal of Gynecological Pathology26418425. doi:10.1097/pgp.0b013e31804216a0.

KleinbergLFlorenesVASilinsIHaugKTropeCGNeslandJMDavidsonB2007Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer109228238. doi:10.1002/cncr.22426.

KommossSdu BoisARidderRTrunkMJSchmidtDPfistererJKommossF2007Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. British Journal of Cancer96306313. doi:10.1038/sj.bjc.6603531.

KonnoRTakanoTSatoSYajimaA2000Serum soluble Fas level as a prognostic factor in patients with gynecological malignancies. Clinical Cancer Research635763580.

KonstantinidouAEKorkolopoulouPVassilopoulosITsengaAThymaraIAgapitosEPatsourisEDavarisP2003Reduced retinoblastoma gene protein to Ki-67 ratio is an adverse prognostic indicator for ovarian adenocarcinoma patients. Gynecological Oncology88369378. doi:10.1016/S0090-8258(02)00092-6.

KonstantinopoulosPASpentzosDKarlanBYTaniguchiTFountzilasEFrancoeurNLevineDACannistraSA2010Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. Journal of Clinical Oncology2835553561. doi:10.1200/JCO.2009.27.5719.

KorkolopoulouPVassilopoulosIKonstantinidouAEZorzosHPatsourisEAgapitosEDavarisP2002The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients. Gynecological Oncology85404414. doi:10.1006/gyno.2002.6627.

KudohKIchikawaYYoshidaSHiraiMKikuchiYNagataIMiwaMUchidaK2002Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer. International Journal of Cancer99579582. doi:10.1002/ijc.10331.

LambeckAJCrijnsAPLeffersNSluiterWJten HoorKABraidMvan der ZeeAGDaemenTNijmanHWKastWM2007Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clinical Cancer Research1323852391. doi:10.1158/1078-0432.CCR-06-1828.

LassusHLeminenAVayrynenAChengGGustafssonJAIsolaJButzowR2004ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecological Oncology923139. doi:10.1016/j.ygyno.2003.10.010.

LeeYHHeoJHKimTHKangHKimGKimJChoSHAnHJ2011Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. International Journal of Gynecological Pathology30205217. doi:10.1097/PGP.0b013e3182063e71.

LevesqueMAKatsarosDMassobrioMGentaFYuHRichiardiGFracchioliSDurandoAArisioRDiamandisEP2000Evidence for a dose–response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. Clinical Cancer Research632603270.

LevidouGKorkolopoulouPThymaraIVassilopoulosISaettaAAGakiopoulouHKonstantinidouAKairi-VassilatouEPavlakisKPatsourisE2007Expression and prognostic significance of cyclin D3 in ovarian adenocarcinomas. International Journal of Gynecological Pathology26410417. doi:10.1097/pgp.0b013e31804630a7.

LuoLYKatsarosDScorilasAFracchioliSPiccinnoRRigault de la LongraisIAHowarthDJDiamandisEP2001Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clinical Cancer Research723722379.

MarthCFieglHZeimetAGMuller-HolznerEDeiblMDopplerWDaxenbichlerG2004Interferon-gamma expression is an independent prognostic factor in ovarian cancer. American Journal of Obstetrics and Gynecology19115981605. doi:10.1016/j.ajog.2004.05.007.

MasciulloVScambiaGMaroneMGiannitelliCFerrandinaGBellacosaABenedetti PaniciPMancusoS1997Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas. International Journal of Cancer74390395. doi:10.1002/(SICI)1097-0215(19970822)74:4<390::AID-IJC5>3.0.CO;2-Q.

MasciulloVFerrandinaGPucciBFanfaniFLovergineSPalazzoJZannoniGMancusoSScambiaGGiordanoA2000p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clinical Cancer Research648164822.

MaternaVSurowiakPMarkwitzESpaczynskiMDrag-ZalesinskaMZabelMLageH2007Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. Oncology Reports17505516.

MedenHMarxDRaabTKronMSchauerAKuhnW1995EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. Journal of Obstetrics and Gynaecology21167178.

Milde-LangoschKHagenMBambergerAMLoningT2003Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer. International Journal of Gynecological Pathology22168174. doi:10.1097/00004347-200304000-00009.

MokSCBonomeTVathipadiekalVBellAJohnsonMEWongKKParkDCHaoKYipDKDonningerH2009A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell16521532. doi:10.1016/j.ccr.2009.10.018.

MooreRGMcMeekinDSBrownAKDiSilvestroPMillerMCAllardWJGajewskiWKurmanRBastRCJrSkatesSJ2009A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecological Oncology1124046. doi:10.1016/j.ygyno.2008.08.031.

MooreRGJabre-RaughleyMBrownAKRobisonKMMillerMCAllardWJKurmanRJBastRCSkatesSJ2010Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. American Journal of Obstetrics and Gynecology203228.e1228.e6. doi:10.1016/j.ajog.2010.03.043.

NewcombEWSosnowMDemopoulosRIZeleniuch-JacquotteASorichJSpeyerJL1999Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. American Journal of Pathology154119125. doi:10.1016/S0002-9440(10)65258-3.

NielsenJSJakobsenEHolundBBertelsenKJakobsenA2004Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. International Journal of Gynecological Cancer1410861096. doi:10.1111/j.1048-891X.2004.14606.x.

Plisiecka-HalasaJKarpinskaGSzymanskaTZiolkowskaIMadryRTimorekADebniakJUlanskaMJedrykaMChudecka-GlazA2003P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens. Annals of Oncology1410781085. doi:10.1093/annonc/mdg299.

PsyrriAKassarMYuZBamiasAWeinbergerPMMarkakisSKowalskiDCampRLRimmDLDimopoulosMA2005Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clinical Cancer Research1186378643. doi:10.1158/1078-0432.CCR-05-1436.

PsyrriAYuZBamiasAWeinbergerPMMarkakisSKowalskiDCampRLRimmDLDimopoulosMA2006Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis. Cancer Epidemiology, Biomarkers & Prevention1511791183. doi:10.1158/1055-9965.EPI-06-0120.

ReimerDSadrSWiedemairAStadlmannSConcinNHofstetterGMuller-HolznerEMarthCZeimetAG2007Clinical relevance of E2F family members in ovarian cancer – an evaluation in a training set of 77 patients. Clinical Cancer Research13144151. doi:10.1158/1078-0432.CCR-06-0780.

RelesAWenWHSchmiderAGeeCRunnebaumIBKilianUJonesLAEl-NaggarAMinguillonCSchonbornI2001Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clinical Cancer Research729842997.

RiedingerJMWafflartJRicolleauGEcheNLarbreHBasuyauJPDalifardIHaceneKPichonMF2006CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Annals of Oncology1712341238. doi:10.1093/annonc/mdl120.

RienerEKArnoldNKommossFLauingerSPfistererJ2004The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. Gynecological Oncology958994. doi:10.1016/j.ygyno.2004.06.048.

RosenDGYangGDeaversMTMalpicaAKavanaghJJMillsGBLiuJ2006Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer10619251932. doi:10.1002/cncr.21767.

RossJSYangFKallakuryBVSheehanCEAmbrosRAMuracaPJ1999HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. American Journal of Clinical Pathology111311316.

RubinSCFinstadCLWongGYAlmadronesLPlanteMLloydKO1993Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. American Journal of Obstetrics and Gynecology168162169.

RustinGJGenningsJNNelstropAECovarrubiasHLambertHEBagshaweKD1989Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. Journal of Clinical Oncology716671671.

SawadaKRadjabiARShinomiyaNKistnerEKennyHBeckerARTurkyilmazMASalgiaRYamadaSDVande WoudeGF2007c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Research6716701679. doi:10.1158/0008-5472.CAN-06-1147.

ScambiaGTestaUBenedetti PaniciPFotiEMartucciRGadducciAPerilloAFacchiniVPeschleCMancusoS1995Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. British Journal of Cancer71354356. doi:10.1038/bjc.1995.71.

SchmiderAGeeCFriedmannWLukasJJPressMFLichteneggerWRelesA2000p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. Gynecological Oncology77237242. doi:10.1006/gyno.2000.5748.

Schmider-RossAPirsigOGottschalkEDenkertCLichteneggerWRelesA2006Cyclin-dependent kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer. Journal of Cancer Research and Clinical Oncology132163170. doi:10.1007/s00432-005-0057-5.

SchuyerMvan der BurgMEHenzen-LogmansSCFieretJHKlijnJGLookMPFoekensJAStoterGBernsEM2001Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. British Journal of Cancer8513591367. doi:10.1054/bjoc.2001.2101.

SecordAALeePSDarcyKMHavrileskyLJGraceLAMarksJRBerchuckA2006Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. Gynecological Oncology101390397. doi:10.1016/j.ygyno.2006.02.014.

SeveldaPSchemperMSponaJ1989CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. American Journal of Obstetrics and Gynecology16112131216.

SillanpaaSAnttilaMVoutilainenKRopponenKTurpeenniemi-HujanenTPuistolaUTammiRTammiMSironenRSaarikoskiS2007Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecological Oncology104296303. doi:10.1016/j.ygyno.2006.09.004.

SimsAHSmethurstGJHeyYOkoniewskiMJPepperSDHowellAMillerCJClarkeRB2008The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets – improving meta-analysis and prediction of prognosis. BMC Medical Genomics142doi:10.1186/1755-8794-1-42.

SkirnisdottirISorbeBSeidalT2001P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. International Journal of Gynecological Cancer11147158. doi:10.1046/j.1525-1438.2001.01003.x.

SkirnisdottirISeidalTSorbeB2004A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. International Journal of Gynecological Cancer14259270. doi:10.1111/j.1048-891X.2004.014209.x.

SkirnisdottirIASorbeBLindborgKSeidalT2011Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage (FIGO I–II) epithelial ovarian cancer. International Journal of Gynecological Cancer21236244. doi:10.1097/IGC.0b013e31820986e5.

Smith-SorensenBKaernJHolmRDorumATropeCBorresen-DaleAL1998Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. British Journal of Cancer78375381. doi:10.1038/bjc.1998.502.

SuhDSYoonMSChoiKUKimJY2008Significance of E2F-1 overexpression in epithelial ovarian cancer. International Journal of Gynecological Cancer18492498. doi:10.1111/j.1525-1438.2007.01044.x.

SuiLDongYOhnoMSugimotoKTaiYHandoTTokudaM2001Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecological Oncology835663. doi:10.1006/gyno.2001.6308.

SuiLDongYOhnoMWatanabeYSugimotoKTokudaM2002Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. International Journal of Oncology21315320.

TaiYTLeeSNiloffEWeismanCStrobelTCannistraSA1998BAX protein expression and clinical outcome in epithelial ovarian cancer. Journal of Clinical Oncology1625832590.

TamKFLiuVWLiuSSTsangPCCheungANYipAMNganHY2007Methylation profile in benign, borderline and malignant ovarian tumors. Journal of Cancer Research and Clinical Oncology133331341. doi:10.1007/s00432-006-0178-5.

TanPKDowneyTJSpitznagelELJrXuPFuDDimitrovDSLempickiRARaakaBMCamMC2003Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Research3156765684. doi:10.1093/nar/gkg763.

TCGAIntegrated genomic analyses of ovarian carcinomaNature4742011609615. doi:10.1038/nature10166.

TempferCHeflerLHeinzlHLoeschAGitschGRumpoldHKainzC1998CYFRA21-1 serum levels in women with adnexal masses and inflammatory diseases. British Journal of Cancer7811081112. doi:10.1038/bjc.1998.636.

ThrallMGallionHHKryscioRKapaliMArmstrongDKDeLoiaJA2006BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. International Journal of Gynecological Cancer16 (Suppl 1) 166171. doi:10.1111/j.1525-1438.2006.00504.x.

TorngPLMaoTLChanWYHuangSCLinCT2004Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecological Oncology92559567. doi:10.1016/j.ygyno.2003.11.011.

TothillRWTinkerAVGeorgeJBrownRFoxSBLadeSJohnsonDSTrivettMKEtemadmoghadamDLocandroB2008Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical Cancer Research1451985208. doi:10.1158/1078-0432.CCR-08-0196.

WangYHellandAHolmRSkomedalHAbelerVMDanielsenHETropeCGBorresen-DaleALKristensenGB2004TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. British Journal of Cancer90678685. doi:10.1038/sj.bjc.6601537.

WidschwendterAMullerHMHubalekMMWiedemairAFieglHGoebelGMueller-HolznerEMarthCWidschwendterM2004Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecological Oncology93407416. doi:10.1016/j.ygyno.2004.01.036.

WismanGBHollemaHHelderMNKnolAJVan der MeerGTKransMDe JongSDe VriesEGVan der ZeeAG2003Telomerase in relation to expression of p53, c-Myc and estrogen receptor in ovarian tumours. International Journal of Oncology2314511459.

Information

Cited By

PubMed

Google Scholar

Related Articles

Altmetrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 151 151 151
PDF Downloads 17 17 17